BioSpace News Archive

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R) announced today that the U.S. Food & Drug Administration (“FDA”) has granted the Company’s Type C meeting request to obtain agreement on the revised protocol endpoints for the Company’s Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine.

A Vancouver-based therapeutics company has received regulatory approval to begin the second Phase II trial of its novel long lasting non-opioid pain medication.

ViewRay, Inc. (NASDAQ: VRAY) announced today that Chindex Medical Limited (Chindex), through its subsidiary, has ordered 10 MRIdian® MR-Guided Therapy Systems.

A research team led by Hospital for Special Surgery Research Institute, in collaboration with Weill Cornell Medicine, has been awarded two grants, one from the Department of Defense and one from the National Institutes of Health, to conduct groundbreaking research regarding lupus flares.1 Sun exposure can trigger skin lesions and worsening of kidneys or other internal organs affected by lupus, but how inflammation at the skin leads to internal organ effects is unknown.

In the context of a major resurgence of the COVID epidemic, the French biotech XENOTHERA announces recent data in favor of the strong interest of its glyco-humanized polyclonal antibody (GH-pAb) XAV-19 to treat patients in the initial viral phase of the disease.

Theranexus and the Beyond Batten Disease Foundation, have announced the initial results of their Phase I/II clinical trial for juvenile Batten disease.

Cardiac Insight, Inc. announced that researchers at Stanford Medicine selected the company’s Cardea SOLO™ wearable ECG system for a medical study entitled: Serial 7-Day Electrocardiogram Patch Screening for Atrial Fibrillation in High-Risk Older Women by the CHARGE-AF Score The study set out to measure asymptomatic atrial fibrillation in older women since AF is associated with an increased risk of stroke.

ScribeEMR, a leading provider of real-time medical scribe and practice management services, has been certified SOC type 2 compliant.

Viridian Therapeutics, Inc. announced that a majority of the independent directors serving on the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to an employee to purchase up to 35,000 shares of the Company’s common stock on January 3, 2023.

Arcutis Biotherapeutics, Inc. reported the grant of an aggregate of 17,050 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 33,550 shares of Arcutis’ common stock to five newly hired employees.